Company Information

    Neurodon was founded on April 2012. The company is based in Schererville, IN, USA . The number of employees in Neurodon is less than 10. Neurodon is a biopharmaceutical company focusing on developing new medicines to improve memory and cognition in alzheimer's disease.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Neurodon has received 3 rounds of venture funding. The total funding amount is around $2.5M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Neurodon - Blog

                          • Curative Potential for Diabetes, Alzheimer’s, and Parkinson’s

                          • Press Release Curative Potential for Diabetes, Alzheimer’s, and Parkinson’s October 26, 2021 Neurodon’s diabetes drug NDC-0009 has the potential to treat both Type 1 and Type 2 diabetes. CROWN POINT — Neurodon Corp. reported that a pharmaceutical industry veteran, who spearheaded the development [...]The post Curative Potential for Diabetes, Alzheimer’s, and Parkinson’s appeared first on Neurodon.
                          • Neurodon Scientists Validated a New Way to Halt Brain Cell Loss

                          • Press Release Neurodon Scientists Validated a New Way to Halt Brain Cell Loss February 5, 2018 We have published an innovative treatment for stroke, traumatic brain injury, and Alzheimer's disease Neurodon, a leader in disease-modifying treatments for neurodegenerative diseases like Parkinson’s, Alzheimer’s, and [...]The post Neurodon Scientists Validated a New Way to Halt Brain Cell Loss appeared first on Neurodon.
                          • Neurodon Awarded Phase I NIH STTR Grant

                          • Press Release Neurodon Awarded Phase I NIH STTR Grant September 24, 2018 The awarded Phase I NIH STTR Grant will be used for Alzheimer’s Disease Drug Discovery Neurodon, an Indiana-based biotech company, has received a Phase I Small Business Technology Transfer (STTR) grant [...]The post Neurodon Awarded Phase I NIH STTR Grant appeared first on Neurodon.
                          • Neurodon Receives Funding from Elevate Ventures

                          • Press Release Neurodon Receives Funding from Elevate Ventures January 4, 2019 Neurodon Receives Funding from Elevate Ventures Through the 21st Century Research & Technology Fund Neurodon, an Indiana-based biotech company, has received a Phase I Small Business Technology Transfer (STTR) grant from the NIH to [...]The post Neurodon Receives Funding from Elevate Ventures appeared first on Neurodon.
                          • SERCA Activator May Improve Memory and Cognition for Alzheimer’s Patients

                          • Press Release SERCA Activator may Improve Memory and Cognition for Alzheimer’s Patients May 9, 2020 Published study reports neuroprotective molecule could improve memory and cognition, while reducing Alzheimer’s degradation WEST LAFAYETTE, Ind. – A Purdue University graduate and a Purdue Research Park of Northwest [...]The post SERCA Activator May Improve Memory and Cognition for Alzheimer’s Patients appeared first on Neurodon.
                          • Neurodon Welcomes Brunde Broady

                          • Press Release Neurodon Welcomes Brunde Broady to its Board of Directors October 3, 2019 Neurodon announced today the appointment of experienced business leader Brunde Broady to the company’s board of directors, effective immediately. Brunde's knowledge and interest in our therapeutic strategy and biological [...]The post Neurodon Welcomes Brunde Broady appeared first on Neurodon.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *